Publications by authors named "Tsukasa Nishizawa"
Background: Tocilizumab is effective in treating severe coronavirus disease 2019 (COVID-19). However, the specific time point it acts as a valid indicator of treatment efficacy remains unclear. This study aimed to determine the optimal day for assessing the prognostic value of the oxygen saturation/fraction of inspired oxygen (SpO/FiO) and ratio of respiratory rate-oxygenation (ROX) index in patients receiving tocilizumab for COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- Anti-aminoacyl-tRNA synthetase (ARS) antibody-positive patients can develop anti-synthetase syndrome (ASS), characterized by symptoms like interstitial lung disease (ILD), especially after treatment with immune checkpoint inhibitors (ICIs).
- A case study of a 47-year-old man with lung adenocarcinoma revealed that after receiving ICI therapy, he developed fever, cough, and confirmed ASS-ILD linked to elevated anti-ARS antibodies.
- Monitoring anti-ARS antibody levels before starting ICI treatment might help predict the risk of developing ASS-ILD in patients.
The hepatitis C virus (HCV) causes acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma, as well as extrahepatic manifestations such as malignant lymphoma. Currently, direct-acting antiviral agents (DAAs) against HCV infection can lead to a sustained virological response (SVR) in almost all HCV-infected patients. In this review article, we discuss acute exacerbation and alanine aminotransferase (ALT) flare in patients with chronic HCV infection.
View Article and Find Full Text PDFBackground: The programmed cell death 1 (PD-1) inhibitor pembrolizumab is a promising agent for treatment of several different malignancies, but as with all immunotherapy there is a potential risk of immune-related adverse events. Adrenocorticotropic hormone (ACTH) deficiency and hypophysitis have been reported in patients treated with a different PD-1 inhibitor, nivolumab. However, clinical characteristics of these side effects associated with pembrolizumab have yet to be described in detail.
View Article and Find Full Text PDFMyotonic dystrophy type 1 (DM1) is an autosomal dominant disease characterized by progressive muscle weakness and myotonia along with multiple organ system involvements. Overall, DM1 patients show reduced life expectancy, mainly due to respiratory or cardiac abnormalities. Chronic respiratory impairment is associated with increased morbidity in DM1.
View Article and Find Full Text PDF